7.3 Inborn Errors of Metabolism & Endocrine Disorders

7.3 Inborn Errors of Metabolism & Endocrine Disorders

Inborn errors of metabolism (IEMs) and neonatal endocrine emergencies represent high-stakes diagnostic dilemmas in neonatal medicine. Individually rare, their collective incidence approaches 1 in 1,500 to 2,500 live births. Because early clinical signs mimic neonatal sepsis or hypoxic-ischemic encephalopathy, diagnostic delay can lead to irreversible central nervous system injury or death. Rapid execution of first-line diagnostic screening and aggressive catabolic suppression are paramount nursing priorities.

1. Clinical Approach to the Neonate with Suspected IEM

The Classic "Symptom-Free Interval"

The hallmark clinical presentation of an inborn error of metabolism is a full-term, well-developed infant with normal Apgar scores who transitions smoothly at birth, experiences a symptom-free interval of 24 to 72 hours, and then undergoes acute, catastrophic deterioration following the introduction of enteral feedings containing dietary protein, galactose, or branched-chain amino acids.

+------------------------------------------------------------------------------------------------------+
|                                 THE IEM CLINICAL PRESENTATION SEQUENCE                               |
|                                                                                                      |
|   Healthy Term Birth (Apgars 8/9)  ──▶  Symptom-Free Interval (24–72h)                               |
|                                                  │                                                   |
|                                                  ▼  [Introduction of Milk Feeds: Protein/Lactose]    |
|   Toxic Intermediate Accumulation  ──▶  Acute Catastrophic Decompensation                            |
|                                                  │                                                   |
|             ├───────────────────┬────────────────┴──────────────────┬────────────────────┐           |
|             ▼                   ▼                                   ▼                    ▼           |
|   [Gastrointestinal]    [Respiratory]                       [Neurological]       [Specific Odors]    |
|   * Poor feeding        * Deep Hyperpnea (Metabolic Acid)   * Lethargy ──▶ Coma  * Musty (PKU)       |
|   * Severe Vomiting     * Rapid Tachypnea (Respiratory Alk) * Hypotonia/Cycling  * Maple Syrup (MSUD)|
|   * Hepatomegaly        * Apnea                             * Intractable Seizure* Sweaty Feet (IVA) |
+------------------------------------------------------------------------------------------------------+

Clinical Signs & Symptoms

• Gastrointestinal: Poor feeding, feed refusal, recurrent projectile or non-bilious vomiting (frequently misdiagnosed as hypertrophic pyloric stenosis or gastroesophageal reflux), massive hepatomegaly, and progressive liver failure.
• Respiratory: Abnormal breathing patterns: deep, unlabored hyperpnea (Kussmaul breathing compensating for profound metabolic acidosis) OR rapid central neurogenic tachypnea (respiratory alkalosis induced by ammonia stimulation of the medullary respiratory center).
• Neurological: Progressive encephalopathy starting with lethargy, somnolence, and hypotonia, advancing to hypertonia, extensor posturing, abnormal motor automatisms (bicycling, rowing, tongue-thrusting), and intractable neonatal seizures refractory to standard anticonvulsants (phenobarbital), culminating in deep coma.
• Characteristic Body & Urine Odors:
  • Musty / Mousy odor: Phenylketonuria (PKU)
  • Maple syrup / Burnt sugar odor: Maple Syrup Urine Disease (MSUD)
  • Sweaty feet / Acrid odor: Isovaleric Acidemia (IVA) or Glutaric Acidemia Type II
  • Boiled cabbage / Rotten butter odor: Tyrosinemia Type I
  • Rotten fish odor: Trimethylaminuria

2. The Tier-1 Emergency Diagnostic Laboratory Workup

When an inborn error of metabolism is suspected, five essential laboratory tests must be obtained simultaneously and immediately prior to modifying IV fluids or administering medications.

First-Line Emergency Laboratory Evaluation Matrix

3. Emergency Medical Stabilization Protocols

Emergency medical management of suspected IEM must be initiated immediately while awaiting definitive biochemical and genetic confirmation:

+------------------------------------------------------------------------------------------------------+
|                                 EMERGENCY IEM STABILIZATION PILLARS                                  |
|                                                                                                      |
|   [Pillar 1: Substrate Cessation] ──▶  Strictly NPO (Halt all protein, lactose, leucine intake)      |
|   [Pillar 2: Anabolic Promotion]  ──▶  High GIR (10–12 mg/kg/min D10W/D15W) + Insulin Infusion       |
|   [Pillar 3: Toxin Clearance]     ──▶  Sodium Phenylacetate/Benzoate (Ammonul) + L-Arginine          |
|   [Pillar 4: Renal Replacement]   ──▶  Emergency Hemodialysis / CVVHD (Ammonia >400–500 μmol/L)      |
|   [Pillar 5: Cofactor Cocktail]   ──▶  L-Carnitine, Hydroxocobalamin (B12), Biotin, Thiamine, B6     |
+------------------------------------------------------------------------------------------------------+

1. Immediate Cessation of Offending Substrates: Place infant strictly NPO. Discontinue all enteral feedings (breast milk, standard infant formulas, protein fortifiers) to halt the exogenous influx of toxic precursor amino acids and galactose.
2. Promote Anabolism & Suppress Catabolism: Infuse intravenous dextrose at a high Glucose Infusion Rate (GIR) of 10 to 12 mg/kg/min using D10W or D15W via a secure central venous catheter. Supplying sufficient non-protein calories drives endogenous insulin release, which halts intracellular proteolysis and catabolism of endogenous muscle proteins. If hyperglycemia (> 200 mg/dL) develops, initiate a continuous intravenous regular insulin infusion (0.05 to 0.1 units/kg/hour) rather than decreasing the GIR, maintaining cellular glucose uptake and anabolic suppression.
3. Pharmacological Nitrogen Scavenging: In neonates with hyperammonemia, administer intravenous Sodium Phenylacetate and Sodium Benzoate (Ammonul). Sodium benzoate conjugates with glycine to form hippurate, while sodium phenylacetate conjugates with glutamine to form phenylacetylglutamine; both conjugate products are excreted rapidly by the kidneys, clearing waste nitrogen independently of the defective urea cycle. Co-administer intravenous L-Arginine or L-Citrulline.
4. Emergency Hemodialysis / Continuous Renal Replacement Therapy (CRRT / CVVHD): Absolute indication when plasma ammonia exceeds 400 to 500 μmol/L, if ammonia is rapidly rising despite scavengers, or in intractable metabolic acidosis. Continuous venovenous hemodiafiltration (CVVHD) is the extracorporeal modality of choice in the NICU (peritoneal dialysis is far too slow and completely inadequate for hyperammonemic emergencies).
5. Empirical Cofactor Administration: Administer intravenous L-Carnitine (binds toxic acyl-CoA intermediates forming non-toxic acylcarnitines excreted in urine), Hydroxocobalamin (Vitamin B12), Biotin, Thiamine (B1), and Pyridoxine (B6).

4. Specific Common Inborn Errors of Metabolism

Phenylketonuria (PKU)

• Etiology: Autosomal recessive deficiency of the hepatic enzyme phenylalanine hydroxylase (PAH), which converts the essential amino acid phenylalanine (Phe) to tyrosine. Phenylalanine and toxic phenylketone metabolites (phenylpyruvate, phenyllactate) accumulate in blood and cerebrospinal fluid.
• Pathophysiology & Neurotoxicity: High phenylalanine concentrations competitively block large neutral amino acid transport across the blood-brain barrier, impairing cerebral protein synthesis, inhibiting myelin formation, and depleting dopamine and serotonin neurotransmitters.
• Clinical Manifestations: Infants appear entirely normal at birth. If untreated, irreversible intellectual disability (IQ $<30$), microcephaly, epilepsy, severe behavioral disturbances, generalized eczematous rash, hypopigmentation (blonde hair, fair skin, blue eyes due to deficient tyrosine-derived melanin), and a characteristic musty or mousy body odor develop over the first months of life.
• Newborn Screening & Diagnosis: State dried blood spot screening (tandem mass spectrometry) reveals elevated blood phenylalanine (> 120 μmol/L or > 2 mg/dL) and an elevated Phe-to-tyrosine ratio, collected 24 to 48 hours after protein ingestion.
• Management: Lifelong strict dietary restriction of phenylalanine initiated within the first 1 to 2 weeks of life. Nutrition consists of a specialized phenylalanine-free medical amino acid formula supplemented with measured amounts of natural breast milk or infant formula to maintain blood Phe levels strictly between 120 and 360 μmol/L (2 to 6 mg/dL). Avoid all aspartame.

Classic Galactosemia

• Etiology: Autosomal recessive deficiency of galactose-1-phosphate uridyltransferase (GALT). The infant cannot metabolize galactose (derived from the hydrolysis of lactose in breast milk and cow's milk formula into glucose and galactose).
• Pathophysiology: Ingestion of lactose leads to rapid, toxic accumulation of galactose-1-phosphate in hepatocytes, renal tubular cells, and the brain, as well as galactitol accumulation in the ocular lens.
• Clinical Manifestations: Onset within days of milk feeding: recurrent vomiting, diarrhea, failure to thrive, lethargy, marked hepatosplenomegaly, hepatic dysfunction, severe unconjugated/conjugated hyperbilirubinemia, renal Fanconi syndrome, "oil-droplet" nuclear cataracts, and life-threatening Escherichia coli (E. coli) sepsis / bacteremia (galactose-1-phosphate impairs polymorphonuclear neutrophil phagocytosis and bactericidal activity).
• Diagnosis: Positive urine reducing substances (Clinitest) accompanied by a negative urine glucose dipstick; confirmed by red blood cell GALT enzyme activity assay.
• Management: Immediate, complete, lifelong elimination of all dietary lactose and galactose. Switch immediately to soy-based infant formula (e.g., Isomil, ProSobee) or elemental formula. Breastfeeding and cow's milk formulas are strictly contraindicated.

5. Neonatal Endocrine Emergencies

Congenital Hypothyroidism (CH)

• Etiology: Most common preventable cause of intellectual disability (1 in 2,000 to 3,000 live births). Caused by thyroid dysgenesis (aplasia, hypoplasia, or ectopic thyroid gland in 85%) or thyroid dyshormonogenesis (inborn errors of thyroid hormone synthesis in 15%).
• Clinical Manifestations: Often clinically silent at birth due to maternal thyroxine (T4) crossing the placenta. Hallmark features emerging over weeks include:
  • Prolonged, persistent unconjugated hyperbilirubinemia (> 2 weeks)
  • Wide/large posterior fontanelle (> 0.5 cm)
  • Prominent umbilical hernia
  • Macroglossia (thick, enlarged protruding tongue causing noisy breathing)
  • Generalized hypotonia, lethargy, poor feeding, hoarse cry
  • Hypothermia, cool, mottled, dry skin, severe constipation, and delayed meconium passage
• Screening & Diagnosis: Newborn blood spot screening measures elevated TSH (> 20 to 40 mIU/L) and/or low total/free T4. Confirmed via venous serum free T4 and TSH.
• Management: Immediate oral Levothyroxine (L-thyroxine / Synthroid) at 10 to 15 mcg/kg/day PO initiated within the first 1 to 2 weeks of life. Tablets should be crushed and mixed with a few milliliters of breast milk or water and given on an empty stomach. Do not mix with soy formula, iron, or calcium (severely impairs GI absorption).

Congenital Adrenal Hyperplasia (CAH)

• Etiology: Autosomal recessive disorder of adrenal steroidogenesis, > 90% caused by 21-hydroxylase deficiency (CYP21A2 gene mutation). Deficiency blocks conversion of 17-hydroxyprogesterone (17-OHP) to 11-deoxycortisol (cortisol precursor) and progesterone to 11-deoxycorticosterone (aldosterone precursor).
• Pathophysiology: Cortisol deficiency eliminates negative feedback on the pituitary, causing massive ACTH hypersecretion. Unchecked ACTH stimulates adrenal cortical hyperplasia and shunts steroid precursors into the adrenal androgen pathway, producing massive androgen excess.

+------------------------------------------------------------------------------------------------------+
|                                 CAH 21-HYDROXYLASE DEFICIENCY PATHWAY                                |
|                                                                                                      |
|   Cholesterol  ──▶  Progesterone & 17-Hydroxyprogesterone (17-OHP)                                   |
|                               │                                                                      |
|                               X  [21-HYDROXYLASE BLOCK]                                              |
|             ┌─────────────────┴──────────────────────────────┐                                       |
|             ▼                                                ▼                                       |
|   [Cortisol Deficiency] ──▶ ACTH Surge             [Aldosterone Deficiency]                          |
|             │                                                │                                       |
|             ▼  [Precursors Shunted to Androgens]             ▼                                       |
|   **MASSIVE ANDROGEN EXCESS**                      **SALT-WASTING CRISIS (Days 7–14)**               |
|   * 46,XX: Virilized Ambiguous Genitalia           * Hyponatremia (Na+ <125 mEq/L)                   |
|   * 46,XY: Normal Phenotype (Hyperpigmentation)    * Hyperkalemia (K+ >7.0-8.0 mEq/L)                |
|                                                    * Hypovolemic Shock & Dehydration                 |
+------------------------------------------------------------------------------------------------------+

• Clinical Presentation:
  • 46,XX Genital Virilization: Genetic females present at birth with ambiguous genitalia (clitoromegaly, labioscrotal fusion, common urogenital sinus), while internal pelvic organs (uterus, fallopian tubes, ovaries) are completely normal.
  • 46,XY Normal Male Genitalia: Genetic males have normal external male genitalia (subtle scrotal/areolar hyperpigmentation), leading to delayed recognition until crisis.
  • Salt-Wasting Adrenal Crisis (Classic CAH in 75%): Occurs at 1 to 2 weeks of life (days 7 to 14) as maternal steroid support wanes: severe hyponatremia (Na+ < 125 mEq/L), hyperkalemia (K+ > 7.0 to 8.5 mEq/L with peaked T waves and QRS widening), metabolic acidosis, vomiting, poor feeding, failure to regain birth weight, severe hypovolemic dehydration, and cardiovascular collapse/shock.
• Screening & Diagnosis: Newborn screen reveals markedly elevated 17-hydroxyprogesterone (17-OHP). Confirm with serum electrolytes, karyotype (46,XX vs. 46,XY), and pelvic ultrasound.
• Emergency Management of Salt-Wasting Crisis:
  1. Fluid Resuscitation: Immediate 0.9% Normal Saline bolus at 20 mL/kg IV over 20 to 30 minutes; repeat as needed for hypovolemic shock. Add D10W to correct hypoglycemia.
  2. Glucocorticoid Replacement: Immediate intravenous Hydrocortisone (stress dose 25 to 50 mg/m² or 1 to 2 mg/kg IV bolus), followed by continuous or divided dosing. Hydrocortisone replaces vital glucocorticoids and suppresses pituitary ACTH hypersecretion.
  3. Mineralocorticoid Replacement: Once oral feeds resume, initiate oral Fludrocortisone (Florinef 0.05 to 0.2 mg/day PO) and Sodium Chloride supplements (1 to 2 g/day PO).